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Hemodynamic role of arachidonate 12. and 5-lipoxygenases in nephro-
toxic serum nephritis. The role of arachidonate 12- and 5-lipuxygenation
eicosanoids in mediating acute changes in renal hemodynamics was
assessed in nephrotoxic serum nephritis (NSN) in the rat. Following a
single intravenous injection of nephrotoxic serum (NTS), significant
decrements in glomerular filtration rate (GFR) and renal blood flow
(RBF) occurred at one hour, and were associated with increments in
glomerular polymorphonuclear leukocyte (PMN) counts and in the
synthesis of thromboxane (Tx) B2, leukotriene (LT) B4 and 12-hydroxy-
eicosatetraenoic acid (12-HETE). Pretreatment of rats with the arachi-
donate 12-lipoxygenase inhibitor, baicalein, partially but significantly
ameliorated the decrements in GFR and RBF, and blocked the en-
hanced glomerular synthesis of 12-HETE following administration of
NTS. Likewise, pretreatment of rats with the arachidonate 5-lipoxyge-
nase inhibitor, U-66858, partially ameliorated the decrements in GFR
and RBF induced by NTS. Combined pretreatment of rats with baica-
1cm and U-66858 ameliorated the decrements in GFR and RBF to an
extent no different to that of U-66858 alone. In rats pretreated with the
LTB4 receptor antagonist, U-75302, GFR and RBF remained depressed
to levels no different than in animals which received NTS alone. These
observations indicate that in NSN, the acute decrements in GFR and
RBF are partially mediated by 12-HETE and arachidonate 5-lipoxygen-
ation products. Leukotrienes other than LTB4, such as LTD4 and
LTC4, are the likely candidates.
Nephrotoxic serum or Masugi nephritis is the experimental
equivalent of human anti-glomerular basement membrane
(GBM) antibody-mediated infiltrative or exudative form of
glomerulonephritis, and is characterized by acute decrements in
GFR and RBF which occur early (30 mm to 1 hr) following
administration of anti-GBM antibody [1]. We have previously
demonstrated that at this early stage of the disease there is
enhanced glomerular synthesis of the arachidonate 12-lipoxy-
genation and 5-lipoxygenation products 1 2-HETE and LTB4
[2]. The role of these eicosanoids in mediating the decrements
in GFR and RBF in this disease model is unknown, and there
are no definitive reports implicating 12-HETE or LTB4 as
vasoactive mediators in this or other models of renal immune
injury. In this work we used selective pharmacologic inhibition
of glomerular 12-HETE and of leukotriene synthesis as well as
LTB4 receptor antagonism in order to examine the role of these
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eicosanoids in mediating the acute impairment in GFR and RBF
in nephrotoxic serum nephritis.
Methods
Induction of nephrotoxic serum nephritis
NSN was induced in male Munich-Wistar rats weighing 190
to 260 g (Harland Industries, Madison, Wisconsin, USA) by a
single intravenous injection of NTS produced in rabbits by
repeated immunization with rat particulate glomei-ular base-
ment membrane (GBM) in complete Freund's adjuvant. Injec-
tion of 0.25 ml/100 g body wt of this NTS induced marked
proteinuria (260 40 mg/24 hr) and an exudative glomerulone-
phritis characterized by linear deposition of rabbit IgG on the
GBM, assessed by immunofluorescence microscopy, and by
glomerular infiltration of neutrophils assessed by light micros-
copy as previously described [2, 3]. Control rats received
identical doses of non-immune rabbit serum (Pd-Freeze, Bio-
logicals, Rogers, Arkansas, USA). All sera were heat inacti-
vated at 56°C for 30 minutes before use.
Renal physiology studies
These studies were performed at one hour following admin-
istration of NTS and assessed changes in GFR and RBF.
Briefly, rats were anesthetized with an intraperitoneal injection
of thiobutabarbitol (mactin, BYK, Gulden Konstanz, Ger-
many) 12 to 15 mg/100 g body wt, and maintained at 37°C on a
constant temperature table. A tracheostomy tube was placed
and a catheter was inserted into the right jugular vein for
infusion of 2% albumin (Sigma Chemical Co., St. Louis, Mis-
souri, USA) in 0.9% sodium chloride at a rate of 20 ml/kg/hr
throughout the experiment. 3H-inulin (New England Nuclear,
Boston, Massachusetts, USA; 0.5 sCiIml) was added to the
infusion solution and GFR was calculated by measuring the
clearance of 3H-inulin. The right femoral artery was cannulated
with a polyethylene catheter connected via a transducer to a
digital pressure monitor for continuous measurement of mean
arterial pressure and for collection of blood samples. Catheters
were also inserted into the ureters for urine collection. RBF was
measured by an electromagnetic flow probe placed around the
left renal artery and connected to an electromagnetic flow meter
(model 501; Carolina Instruments, King, North Carolina,
USA). Mter completion of surgery and a 60-minute stabiliza-
tion period, two baseline clearance periods (15 mm each) were
obtained, Animals subsequently received a single intravenous
injection of NTS (0.25 ml/lOO g body wt) or non-immune rabbit
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serum (0.25 ml/l00 g body wt) and urine and plasma samples
were collected during two additional 30-minute clearance pen-
ods.
12-Lipoxygenase inhibition studies
To determine whether activation of arachidonate 12-lipoxy-
genase pathway mediates the changes in GFR and RBF induced
by administration of NTS, the selective 12-lipoxygenase inhib-
itor baicalein (5,6,7-trihdroxyflavone, Biomol, Philadelphia,
Pennsylvania, USA) [4] was used. Baicalein (60 mg/kg body wt,
dissolved in 0.5 ml of DMSO) was injected intraperitoneally two
hours prior to baseline GFR and RBF measurements. NTS was
subsequently given and GFR and RBF determinations were
repeated one hour later.
Leukotriene inhibition and antagonism studies
To assess the role of the arachidonate 5-lipoxygenase path-
way in mediating changes in GFR and RBF induced by NTS,
rats were pretreated with the 5-lipoxygenase inhibitor, U-66858
(1 -acetoxy-2-n-butyl-4-methoxy-naphthalene, Upjohn Co.,
Kalamazoo, Michigan, USA) [5]. This compound (30 mg/kg,
dissolved in 0.5 ml of 70% ethanol) was given orally two hours
prior to administration of NTS via a polyethylene tube inserted
into the stomach.
The role of LTB4 in mediating changes in GFR and RBF
following administration of NTS was assessed using the selec-
tive LTB4 receptor antagonist U-75302 (6-[6-<3-hydroxy-
1 E,5Z-undecadien- 1 -yl>-2-pyridinyl]- 1 ,5-hexanediol, Upjohn
Co.) [6]. U-753C2 (30 mg/kg, dissolved in 0.5 ml of 70% ethanol)
was given orally via a gastric tube two hours prior to adminis-
tration of NTS a .1 GFR and RBF measurements.
Glomerular biochemical studies
Upon completion of renal hemodynamic measurements (1 hr
following NTS of non-immune rabbit serum), animals were
nephrectomized and the kidneys were placed in RPMI-1640 at
4°C. Glomeruli were isolated by differential sieving, suspended
in 2 ml of RPMI-1640 and incubated under constant stirring at
37°C for 30 minutes. At the end of this incubation period, 0.2 ml
of medium was sampled and assayed directly for TxB2 using a
specific RIA for this eicosanoid. The phospholipase A2 activa-
tor A2387 was subsequently added to the glomerular suspension
(final concentration 10 jiM) and a second incubation was per-
formed at 37°C for 45 minutes. This incubation was terminated
by the addition of 2 volumes of acidified ice-cold ethanol.
Following an 18 hour extraction at 4°C the supernatant was
separated from the precipitated protein. The glomerular pellet
was solubilized in NaOH and protein measured by a colorimet-
nc assay. The supernatant was dried under nitrogen, suspended
in 1 ml of HPLC solvent (methanol:water:acetic acid, 64:34:2,
vol/vol/vol), and injected into a gradient HPLC system in order
to separate and isolate 12-HETE and LTB4, which were sub-
sequently quantified using specific RIAs as we have reported
previously [2]. Results were expressed in nanograms of ci-
cosanoid/mg glomerular protein. Sensitivities and cross-reactiv-
ities of RIAs employed for the above eicosanoids were previ-
ously assessed and reported [2]. The antiserum for TxB2 was a
gift from Dr. W. Campbell (Medical College of Wisconsin,
Milwaukee, Wisconsin, USA). The antiserum for LTB4 was
Inc., Dorval, Quebec, Canada). The antibody for 12-HETE was
provided by Dr. L. Levine (Brandeis University, Waltham,
Massachusetts, USA).
Assessment of glomerular leukocyte infiltration
Kidney cortical tissues were fixed by immersion in neutral
buffered formalin and embedded in paraffin. Four-micrometer
sections were stained with hematoxylin and eosin. Infiltrating
polymorphonuclear leukocytes (PMN) were identified and
counted in 20 glomeruli per rat and in two rats from each group.
Results were expressed as mean SE of PMN per glomerulus.
Experimental groups
(1.) NSN and control group. Eleven rats received NTS (0.25
ml/l00 g body wt); 8 rats received non-immune rabbit serum
(0.25 ml/100 g body wt).
(2.) 12-lipoxygenase inhibition group. Rats were pretreated
with the 12-lipoxygenase inhibitor, baicalein (60 mg/kg body
wt), and subsequently received NTS (N = 5) or non-immune
rabbit serum (N = 5).
(3.) 5-lipoxygenase inhibition group. Eight rats were pre-
treated with the 5-lipoxygenase inhibitor, U-66858 (30 mg/kg
body wt: N = 6; 20 mg/kg body wt, N = 2.) and subsequently
received NTS. Because the responses to these two doses were
similar, results of these studies were pooled. In additional
experiments, four rats were sacrificed at one hour following
injection of NTS and glomeruli were isolated as described
above and incubated in the presence of 1 m'vi U-66858 to assess
glomerular eicosanoid synthesis. Five control rats were pre-
treated with U-66858 (30 mg/kg body wt) and subsequently
received non-immune rabbit serum. a
(4.) Combined 12- and 5-lipoxygenase inhibition group. Rats
were pretreated with baicalein (60 mg/kg body wt) and U-66858
(30 mg/kg body wt) and subsequently received NTS (N = 6) or
non-immune rabbit serum (N = 5).
(5.) LTB4 receptor antagonism group. Six rats received the
LTB4 receptor antagonist U-75302 (30 mg/kg body wt, N = 4;
60 mg/kg body wt, N = 2) prior to administration of the NTS.
Results of these experiments were pooled as the responses to
the two doses were similar. Five control rats were pretreated
with U-75302 (30 mg/kg body wt) and subsequently received
non-immune rabbit serum.
Statistical analyses
Results are expressed as mean SE. Statistical analyses
were performed using the Student's t-test for unpaired obser-
vations or the two-way analysis of variance for repeated mea-
surements, depending on the experimental design. Statistical
significance was considered as P < 0.05.
Results
As shown in Figures 1 and 2, NTS caused marked decre-
ments in GFR and RBF at one hour. These changes were not
associated with a drop in mean arterial pressure (baseline, 131
21 mm Hg; 1 hr, 127 17 mm Hg). The 12-lipoxygenase
inhibitor, haicalein, partially but significantly ameliorated the
decrements in GFR (Fig. lA) and RBF (Fig. 2A) induced by
NTS without significantly altering mean arterial pressure (base-
provided by Dr. A. Ford-Hutchinson (Merck-Frosst Canada line, 137 8 mm Hg; 1 hr, 140 8 mm Hg). The 5-lipoxygenase
E
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Fig. 1. Effects of inhibition of arachidonate
12-lipoxygenase (JA), of inhibition of
arachidonate 5-lipoxygenase (IB), of
antagonism of LTB4 receptor (IC) and of
combined inhibition of 5- and 12-lipoxygenase
(JD) on NTS-induced decrement in GFR.
Symbols are: (•) NTS; (0) Rabbit serum
inhibitor or antagonist; (Li) NTS + inhibitor
or antagonist. * P < 0.05 compared to
baseline. t P < 0.05 compared to controls
receiving rabbit serum. § P < 0.05 compared
to rats receiving NTS alone.
inhibitor, U-66858, also ameliorated the NTS-induced decre-
ments in GFR and RBF and had no effect on GFR (Fig. 1B) or
RBF (Fig. 2B) in control animals. Combined pretreatment with
U-66858 and baicalein ameliorated the decrements in GFR (Fig.
1D) and RBF (Fig. 2D) induced by NTS to an extent no different
than in the group pretreated with U-66858 alone. The LTB4
receptor antagonist, U-75302, afforded no protection in the
NTS-induced decrements in GFR (Fig. 1C) and RBF (Fig. 2C).
One hour following NTS administration there was enhanced
glomerular synthesis of TxB2, 12-HETE (Fig. 3) and LTB4 (Fig.
4). Pretreatment with the 12-lipoxygenase inhibitor, baicalein,
selectively abolished the increment in glomerular 12-HETE
synthesis but did not alter the enhanced synthesis of TxB2 or
LTB4 (Figs. 3 and 4). While the 5-lipoxygenase inhibitor,
U-66858, did not inhibit glomerular synthesis of LTB4 assessed
in glomeruli isolated following completion of renal physiology
studies and incubated in the absence of this inhibitor, LTB4
synthesis was markedly inhibited in incubations performed in
the presence of U-66858 (Fig. 4).
Figure 5 shows the extent of glomerular infiltration by PMNs.
There was increased glomerular neutrophil infiltration one hour
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Fig. 2. Effects of inhibition of arachidonate
12-lipoxygenase (2A), of inhibition of
arachidonate 5-lipoxygenase (2B), of
antagonism of LTB4 receptor (2C) and of
combined inhibition of 5- and 12-lipoxygenase
(2D) on NTS -induced decrement in RBF.
Symbols are: (•) NTS; (0) Rabbit serum +
inhibitor or antagonist; (is) NTS + inhibitor
or antagonist. * P < 0.05 compared to
baseline. t P < 0.05 compared to controls
receiving rabbit serum. § P < 0.05 compared
to rats receiving NTS alone.1 Hour









Rabbit NTS Baicalein U-66858 U-66858+NTS
serum +NTS +NTS co-incubation
Fig. 4. Effects of inhibition of arachidonate 12- and 5-lipoxygenat ion
on glomerular LTB4 synthesis. * P < 0.05 compared to rats receiving
NTS alone.
U-66858 or U75302, there was a tendency towards reduced
PMN infiltration but the differences did not reach statistical
significance. However, combined pretreatment with baicalein
and U-66858 significantly ameliorated the increment in glomer-
ular PMN infiltration.
Discussion
12-HETE is a major arachidonate 12-lipoxygenation product
and exerts important proinflammatory effects [7—91. Although
enhanced 12-HETE synthesis was found in a number of renal
injury models such as the hydronephrotic kidney [10], ischemic
renal injury [111, mesangioproliferative nephritis [121 and neph-
rotoxic serum nephritis [2, 31, the hemodynamic role of the
enhanced 12-HETE synthesis remains unclear. 12-HETE was
found to be a potent vasoconstrictor of renal arcuate arteries
[111, an observation which raises the possibility that 12-HETE
may play a role in mediating the changes in renal hemodynam-
ics following glomerular immune injury. Indeed, we have
recently reported that platelet-derived 12-HETE may mediate
decrements in RBF in mesangial cell immune injury [13]. In the
present study, pretreatment with the 12-lipoxygenase inhibitor,
baicalein, ameliorated the acute decrements in GFR (Fig. 1A)
Fig. 5. Polymorphonuclear leukocyte counts per glomerular cross sec-
tion in each experimental group. *P < 0.05 compared to controls
receiving rabbit serum. # P < 0.05 compared to rats receiving NTS
alone.
and RBF (Fig. 2A) without changing mean arterial pressure,
and selectively blocked the enhanced glomerular synthesis of
12-HETE (Fig. 3). These observations suggest that 12-HETE
partially mediates the drop in GFR and RBF in NSN.
The mechanisms by which 12-HETE exerts a vasoconstric-
tive effect have been explored by other investigators. 12-HETE
is an inhibitor of Na-K-ATPase in the kidney [14] and could
effect the calcium messenger system in contractile cells such as
the vascular smooth muscle cell of renal arteriols via changes in
cell calcium and/or protein kinase C activity [11, 15]. 12-HETE
also directly activates potassium channels in smooth muscle
cells [16]. In addition, l2-HETE has been shown to serve as a
second messenger for the vasoconstrictor effect of angiotensin
II, as pretreatment with the 12-lipoxygenase inhibitors, baica-
kin or esculetin, attenuated angiotensin Il-mediated vasocon-
striction of rat aortas 117]. However, blockade of angiotensin II
does not prevent anti-GBM antibody-induced vasoconstriction
or reduction in glomerular ultrafiltration coefficient [18], indi-
cating that it is unlikely that angiotensin II mediated the
decrements in GFR or RBF via 12-HETE in our studies.
Baicalein is a relatively selective 12-lipoxygenase inhibitor.
In studies in platelets, baicalein has been shown to inhibit
cyclo-oxygenase activity when used at concentrations 6000
times higher than that needed to inhibit 1 2-lipoxygenase activity
[4]. The doses of baicalein employed in the present experiments
did not inhibit glomerular synthesis of TxB2 or LTB4 (Figs. 3
and 4), indicating that glomerular 12-lipoxygenase was indeed
selectively inhibited by baicalein.
The role of LTs in mediating changes in renal hemodynamics
has also been investigated in several experimental models of
glomerular injury such as murine lupus nephritis [19], obstruc-
tive nephropathy [20], mesangial cell immune injury [13], and
NSN [21, 22]. We and others have demonstrated that there is
enhanced glomerular synthesis of LTB4 in NSN [2, 22, 23] and
a likely source of LTs may be resident glomerular macrophages

















Rabbit NTS Baicalein U66858 Baicalein U75302
serum +NTS +NTS +U66858 +NTS
+NTS
Fig. 3. Effects of inhibition of arachidonate 12-lipoxygenation on gb-
merular TxB2 and 12-HETE synthesis. Symbols are: (U) rabbit serum;() NTS; (LI) NTS + baicalein. * P < 0,05 compared to controls
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these cells may cause arteriolar vasoconstriction via the release
of LTs and reduce the glomerular capillary ultrafiltration coef-
ficient [13]. LTC4 and LTD4 have been shown to contract
glomerular mesangial cells and constrict renal vasculature [26,
27] and to cause a fall in the ultrafiltration coefficient and GFR
when administered exogenously to normal rats [28, 29]. In
contrast, LTB4 has no spasmogenic activity on cultured mesan-
gial cells or rat or rabbit aorta [26, 30], and produces no fall in
GFR or renal plasma flow when administered to normal rats
[221. In the present studies, inhibition of 5-lipoxygenase by
U-66858 partially ameliorated the fall in GFR (Fig. lB) and RBF
(Fig. 2B) induced by NTS, but antagonism of the LTB4 receptor
with 1J-75302 had no ameliorative effects on changes in GFR
(Fig. 1C) or RBF (Fig. 2C). These data implicate LTs other than
LTB4 in mediating the drop in GFR and RBF in NSN, the likely
candidates being LTC4 or LTD4. Indeed, antagonism of the
LTD4 receptor with SKF- 104353 ameliorates the reduction in
GFR and RBF in rats with NSN [21] and murine lupus [19].
LTB4 and l2-HETE are leukocyte chemotactic eicosanoids
[7, 22]. LTB4 administration results in leukocyte infiltration into
glomeruli and potentiates the decrements in GFR and renal
plasma flow in rats with mild NSN, but this eicosanoid does not
increase glomerular leukocyte recruitment when administered
to normal rats [22]. In the present studies there was a tendency
towards reduced PMN infiltration in U-66858, baicalein or
U-75302-treated rats with NSN, but the differences did not
reach statistical significance. U-66858 and baicalein may have
additive effect on reducing PMN infiltration, as combined
pretreatment with these two inhibitors reduced influx of PMN s
into glomeruli (Fig. 5). Our results suggest that chemotactic
factors other than endogenous LTB4 and 12-HETE may also
play a major role in glomeruli following administration of NTS.
Indeed, complement-derived anaphylatoxins (C3a, C5a) medi-
ate leukocyte chemotaxis in NSN, as complement depletion in
rats with NSN prevents the accumulation of leukocytes within
the glomerular capillary and ameliorates the reduction in single
nephron filtration rate by eliminating vasoconstriction [1]. Rich-
ards et al studied the effect of U-75302 on antigen-induced
bronchopulmonary eosinophilia in sensitized guinea pigs [31]
and rats [32]. Doses of U-75302 (1, 10 and 30 mg/kg body wt)
administered orally significantly inhibited the antigen-induced
influx of eosinophils into the bronchial lumen, but the influx of
neutrophils was not affected by treatment with U-75 302 [31, 32].
These studies, therefore, support our interpretation that in the
present studies U-75302 employed in doses (30 and 60 mg/kg
body wt) comparable to those in the studies by Richards et al
did not inhibit infiltration of PMNs into glomeruli.
In the group of rats treated with both baicalein and U-66858,
combined inhibition of 12- and 5-lipoxygenase did not com-
pletely prevent the NTS-induced reductions in GFR (Fig. lD)
and RBF (Fig. 2D). The reason for this lack of an additive effect
is unclear, but one explanation is that I 2-lipoxygenase products
and sulfidopeptide LTs have the same mechanism of action on
renal vasculature. Moreover, several other mediators can be
implicated in the impairment of renal hemodynamics in NSN.
For example, the anaphylatoxin CSa may have an independent
renal vasoconstrictive effect [1, 331; thromboxane [341 and
a-adrenergic activity [18] could also mediate the acute impair-
ment of renal hemodynamics induced by NTS.
U-66858 inhibits the conversion of LTA4 to LTC4 and to
LTD4 as well as the conversion of arachidonic acid to LTC4 and
LTD4 [5]. In the present studies, inhibition of glomerular
synthesis of LTB4 occurred only when glomeruli isolated from
the rats with NSN were incubated in the presence of U-66858
(Fig. 4). This suggests that glomerular 5-lipoxygenase inhibition
in vivo is not apparent when assessed in isolated glomeruli,
possibly due to reversible binding of this compound to its target
protein and a "wash out" effect during glomerular isolation.
In summary, our studies indicate that in NSN, the acute
decrements in GFR and RBF are partially mediated both by
12-HETE and by arachidonate 5-lipoxygenation products. Of
the latter, endogenous LTB4 does not mediate the decrements
in GFR and RBF. Leukotrienes other than LTB4, such as LTD4
and LTC4, are the likely mediators of the decrements in GFR
and RBF.
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